Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1–98

BACKGROUND: The androgen receptor (AR) is an emerging prognostic marker and therapeutic target in breast cancer. AR is expressed in 60–80% of breast cancers, with higher prevalence among estrogen receptor-positive (ER+) tumors. Androgen treatment inhibits ER signaling in ER+/AR+ breast cancer cell l...

Descripción completa

Detalles Bibliográficos
Autores principales: Kensler, Kevin H., Regan, Meredith M., Heng, Yujing J., Baker, Gabrielle M., Pyle, Michael E., Schnitt, Stuart J., Hazra, Aditi, Kammler, Roswitha, Thürlimann, Beat, Colleoni, Marco, Viale, Giuseppe, Brown, Myles, Tamimi, Rulla M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387478/
https://www.ncbi.nlm.nih.gov/pubmed/30795773
http://dx.doi.org/10.1186/s13058-019-1118-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387478/
https://www.ncbi.nlm.nih.gov/pubmed/30795773
http://dx.doi.org/10.1186/s13058-019-1118-z

Ejemplares similares